Client of a consultant lobbyist
RAREi - The Canadian Forum for Rare Disease Innovators
- Meetings this Parliament
- 3
- With MPs
- 2
- Since Nov 2021
- 12
- Active registrations
- 1
Most recent reported meeting: Sep 22, 2026.
Lobbying by RAREi - The Canadian Forum for Rare Disease Innovators: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Raquel Dancho Conservative 1
- Tom Kmiec Conservative 1
Institutions
- House of Commons2
- Health Canada (HC)2
- Innovation, Science and Economic Development Canada (ISED)1
Registrations in effect
Consultant In effect since Mar 1, 2026
Consultant Gerald Jeffcott of 3Sixty Public Affairs
Consultant lobbyists
-
Gerald Jeffcott
Former public office holder
Formerly Constituency Assistant to the Hon. Roy MacLaren, PC, MP, House of Commons, House of Commons (1989–1990)
Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Senate of Canada
What they're lobbying on (7)Hide details
- National pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
- Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada's review of medicines (particularly rare disease treatments).
- Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incenting research and development activities in Canada.
- Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
- Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
- Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Registration 780779-368917-9. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Gerald Jeffcott · Consultant
- Raquel Dancho · Member of Parliament
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Read more
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
-
Reported by Gerald Jeffcott · Consultant
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Justine Frame · Policy Advisor, Health Canada (HC)
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases. Read more
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategy and other government policies and programs related to incenting research and development activities in Canada.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.
-
Reported by Gerald Jeffcott · Consultant
- Tom Kmiec · MP
- Daniel MacDonald · Director General, Office of Pharmaceutical Management Strategies, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations. Read more
National pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
-
Reported by Gerald Jeffcott · Consultant
- Daniel MacDonald · Director General, Health Canada (HC)
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases. Read more
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
-
Reported by Gerald Jeffcott · Consultant
- Guillaume Couillard · Director General, Patented Medicine Prices Review Board (PMPRB)
Industry
-
Reported by Gerald Jeffcott · Consultant
- Daniel MacDonald · Director General, Health Canada (HC)
Health
-
Reported by Gerald Jeffcott · Consultant
- Guillaume Coulliard · Executive Director (acting), Health Canada (HC)
Health
-
Reported by Gerald Jeffcott · Consultant
- Douglas Clark · Executive Director, Patented Medicine Prices Review Board (PMPRB)
Health
-
Reported by Gerald Jeffcott · Consultant
- Michelle Mujoomdar · Director, Specialty Pharmaceuticals, Health Canada (HC)
Health
-
Reported by Gerald Jeffcott · Consultant
- Tanya Potashnik · Director of Policy and Economic Analysis, Patented Medicine Prices Review Board (PMPRB)
Health
-
Reported by Gerald Jeffcott · Consultant
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Health
-
Reported by Gerald Jeffcott · Consultant
- Brent Lawlor · Director, Health Canada (HC)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.